Department of Microbiology and Physiological Systems; Horae Gene Therapy Center
Cellular and Molecular Physiology | Developmental Neuroscience | Nervous System Diseases | Neurology
Haploinsufficiency of the SLC2A1 gene and paucity of its translated product, the glucose transporter-1 (Glut1) protein, disrupt brain function and cause the neurodevelopmental disorder, Glut1 deficiency syndrome (Glut1 DS). There is little to suggest how reduced Glut1 causes cognitive dysfunction and no optimal treatment for Glut1 DS. We used model mice to demonstrate that low Glut1 protein arrests cerebral angiogenesis, resulting in a profound diminution of the brain microvasculature without compromising the blood-brain barrier. Studies to define the temporal requirements for Glut1 reveal that pre-symptomatic, AAV9-mediated repletion of the protein averts brain microvasculature defects and prevents disease, whereas augmenting the protein late, during adulthood, is devoid of benefit. Still, treatment following symptom onset can be effective; Glut1 repletion in early-symptomatic mutants that have experienced sustained periods of low brain glucose nevertheless restores the cerebral microvasculature and ameliorates disease. Timely Glut1 repletion may thus constitute an effective treatment for Glut1 DS.
Rights and Permissions
Copyright © 2017, The Author(s).
DOI of Published Version
Nat Commun. 2017 Jan 20;8:14152. doi: 10.1038/ncomms14152. Link to article on publisher's site
Tang M, Gao G, Li H, Su Q, De Vivo DC, Monani UR. (2017). Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. Open Access Articles. https://doi.org/10.1038/ncomms14152. Retrieved from https://escholarship.umassmed.edu/oapubs/3060
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.